Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies
Stem cell therapies have gone through every stage of the long and painful hype cycle for emerging drug technologies: Starting with wildly inflated early expectations through bitter disillusionment, a trough of despair and on to a slow and patient recovery brought about by years of diligent research work in the lab.
Paul Wotton, who’s seen it all, believes he can now see the off-the-shelf cell products of the future — encapsulated in what they’ve dubbed Afibromer platform tech — taking shape at the end of the newly rising curve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.